Dr. Steven Davis Brings Extensive Chemical and Pharmaceutical Experience; Strengthens Foley’s Already Prominent Intellectual Property Department.
Foley announced today that Dr. Steven G. Davis has joined the firm as a partner in the Boston office, working in the Chemical & Pharmaceutical Practice. Prior to joining Foley, Davis was a principal at Hamilton, Brook, Smith & Reynolds.
Davis focuses his practice on patent prosecution, portfolio strategy and management, freedom to operate assessments, infringement analysis, patent issues related to IPOs, and intellectual property licensing. He assists a variety of clients including universities, start-ups, and major pharmaceutical corporations with protecting technologies in the areas of chemistry, pharmaceuticals, and biotechnology. Davis also advises venture capital investors with due diligence investigations and other clients prior to acquiring intellectual property assets.
“Steven’s addition will help deepen the firm’s already strong capabilities in the chemical and pharmaceutical arenas,” said Sharon Barner, chair of Foley’s Intellectual Property Department. “Having previously worked as an industry professional, Steven’s extensive chemistry background and specific knowledge of the issues currently facing companies will be great assets to our clients doing patent work in these areas. Steven’s addition will also compliment our strong domestic and international Life Sciences practice and provide additional strength in a key area of innovation.”
Davis joins the Boston office following the recent additions of patent litigation attorneys Matthew Lowrie, Aaron Moore and Robert Silverman.
“Steven has a well-deserved reputation as a leading chemical patent attorney in Boston,” said Susan Pravda, managing partner of Foley’s Boston office. “In addition to his experience in the protection and management of chemical and pharmaceutical companies’ technologies, Steven has also developed valuable relationships within Boston’s deep start-up and emerging technologies community that will surely strengthen the firm’s presence in this area.”
Drawing from his industry experience as a research scientist, Davis has practiced patent law both in private practice and as in-house counsel for Eli Lilly and Company. He has co-authored eight scientific publications and is a co-inventor on U.S. Patent 5,073,564 covering photoactivated insecticides.
Comprised of nearly 240 attorneys, Foley’s Intellectual Property practice is a recognized leader in IP legal services. For the eighth consecutive year, Foley was ranked by IP Today as one of the top 10 firms for the number of patents issued and by IP Law & Business magazine as one of the top patent litigation firms in the nation. These rankings make Foley the only general practice firm to appear in the top 10 for both patent litigation and patent procurement.
Foley & Lardner LLP continually evolves to meet the changing legal needs of our clients. Our team-based approach, proprietary client service technology, and practice depth enhance client relationships while seeing clients through their most complex legal challenges. The BTI Consulting Group (Wellesley, Massachusetts) recently recognized Foley as one of the top four law firms shaping the U.S. legal market, while CIO magazine has named Foley to its CIO 100 list six times for our client-focused technology. With more than 1,000 attorneys in 21 offices and more than 50 practices, count on Foley for high-caliber business and legal insight.
Foley announced today that Dr. Steven G. Davis has joined the firm as a partner in the Boston office, working in the Chemical & Pharmaceutical Practice. Prior to joining Foley, Davis was a principal at Hamilton, Brook, Smith & Reynolds.
Davis focuses his practice on patent prosecution, portfolio strategy and management, freedom to operate assessments, infringement analysis, patent issues related to IPOs, and intellectual property licensing. He assists a variety of clients including universities, start-ups, and major pharmaceutical corporations with protecting technologies in the areas of chemistry, pharmaceuticals, and biotechnology. Davis also advises venture capital investors with due diligence investigations and other clients prior to acquiring intellectual property assets.
“Steven’s addition will help deepen the firm’s already strong capabilities in the chemical and pharmaceutical arenas,” said Sharon Barner, chair of Foley’s Intellectual Property Department. “Having previously worked as an industry professional, Steven’s extensive chemistry background and specific knowledge of the issues currently facing companies will be great assets to our clients doing patent work in these areas. Steven’s addition will also compliment our strong domestic and international Life Sciences practice and provide additional strength in a key area of innovation.”
Davis joins the Boston office following the recent additions of patent litigation attorneys Matthew Lowrie, Aaron Moore and Robert Silverman.
“Steven has a well-deserved reputation as a leading chemical patent attorney in Boston,” said Susan Pravda, managing partner of Foley’s Boston office. “In addition to his experience in the protection and management of chemical and pharmaceutical companies’ technologies, Steven has also developed valuable relationships within Boston’s deep start-up and emerging technologies community that will surely strengthen the firm’s presence in this area.”
Drawing from his industry experience as a research scientist, Davis has practiced patent law both in private practice and as in-house counsel for Eli Lilly and Company. He has co-authored eight scientific publications and is a co-inventor on U.S. Patent 5,073,564 covering photoactivated insecticides.
Comprised of nearly 240 attorneys, Foley’s Intellectual Property practice is a recognized leader in IP legal services. For the eighth consecutive year, Foley was ranked by IP Today as one of the top 10 firms for the number of patents issued and by IP Law & Business magazine as one of the top patent litigation firms in the nation. These rankings make Foley the only general practice firm to appear in the top 10 for both patent litigation and patent procurement.
Foley & Lardner LLP continually evolves to meet the changing legal needs of our clients. Our team-based approach, proprietary client service technology, and practice depth enhance client relationships while seeing clients through their most complex legal challenges. The BTI Consulting Group (Wellesley, Massachusetts) recently recognized Foley as one of the top four law firms shaping the U.S. legal market, while CIO magazine has named Foley to its CIO 100 list six times for our client-focused technology. With more than 1,000 attorneys in 21 offices and more than 50 practices, count on Foley for high-caliber business and legal insight.
Related News
03 February 2025
Press Releases
Foley Announces 2025 New Partner Class
Foley & Lardner LLP is pleased to announce the promotion of 17 lawyers to the firm’s partnership, effective February 1, 2025.
17 January 2025
Press Releases
Young Leaders Share Their Dreams for the Future at Foley’s Annual MLK Jr. Oratory Competition
The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP’s Annual MLK Jr. Oratory Competitions.
17 January 2025
Press Releases
Foley Represents Hospice Coalition in Lawsuit Against CMS Special Focus Program
Foley & Lardner LLP is representing a multi-state coalition of hospices and hospice associations in challenging the Centers for Medicare & Medicaid Services’ Hospice Special Focus Program (SFP) Final Rule and List.